icon-folder.gif   Conference Reports for NATAP  
 
  ID Week
Oct 8-12 2014
Philadelphia
Back grey_arrow_rt.gif
 
 
 
ABT-450/R/OMBITASVIR AND DASABUVIR WITH RIBAVIRIN ACHIEVES HIGH SUSTAINED VIROLOGIC RESPONSE RATES REGARDLESS OF BASELINE CHARACTERISTICS: POOLED ANALYSES OF THE SAPPHIRE-I AND SAPPHIRE-II STUDIES
 
 
  Reported by Jules Levin
 
IDWeek 2014
Philadelphia, PA
October 8-12, 2014
 
EASL: TURQUOISE-II: SVR12 RATE OF 92-96% IN 380 HEPATITIS C VIRUS GENOTYPE 1-INFECTED ADULTS WITH COMPENSATED CIRRHOSIS TREATED WITH ABT-450/r/ABT-267 AND ABT-333 PLUS RIBAVIRIN - (04/14/14)
 
EASL: SAPPHIRE-I: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/r/ABT-267, ABT-333, AND RIBAVIRIN IN 631 TREATMENT-NAïVE ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1 - (04/11/14)
 
EASL: SAPPHIRE-II: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/r/ABT-267, ABT-333, AND RIBAVIRIN IN 394 TREATMENT-EXPERIENCED ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1 - (04/10/14)
 
HIV/HCV Coinfection: http://www.natap.org/2014/HCV/090314_06.htm....... ICAAC: TURQUOISE-I: SAFETY AND EFFICACY OF ABT-450/R/OMBITASVIR, DASABUVIR, AND RIBAVIRIN IN PATIENTS CO-INFECTED WITH HEPATITIS C AND HIV-1 - (09/08/14)
 
Jordan J. Feld, Ola Weiland, Rui T. Marinho, Heiner Wedemeyer, Ira M. Jacobson, Donald M. Jensen, Tarek Hassanein, Victor de Ledinghen, Moisés Diago, Lorenzo Magenta, Robert J. De Knegt, Bo Fu, Eoin Coakley, Fernando Tatsch, Graham R. Foster

IDSA1.gif

IDSA2.gif

IDSA3.gif

IDSA4.gif

IDSA5.gif

IDSA6.gif

IDSA8.gif

IDSA8.gif

IDSA9.gif

IDSA10.gif